Between 2000 and 2006, we published a printed CR Summary Report, which was distributed to shareholders alongside our annual reports. Copies of these Summary Reports can be viewed/downloaded in the CR Reports section.
In 2007, we changed our approach and included CR reporting within our Annual Report and Form 20F to reflect our increasing integration of CR-related issues into everyday business management.
This dedicated Responsibility section of our website, which is updated throughout the year, will continue to provide detailed statistics and further information about our CR performance, policies and principles. Our target audience is a wide one – we hope to meet the CR information needs of all our stakeholders and others who have an interest in our business, including CR research and ranking organisations. Please use the Contact Us facility if you have any questions relating to the content of this section of our website.
The performance data, as well as details of our progress throughout this section of our website, refers to the year 1 January – 31 December 2007, unless otherwise indicated.
View a summary of our performance over the last three years.
The Responsibility section of our website covers all the facilities related to our healthcare business, with the exception of KuDOS, Arrow Therapeutics and MedImmune, including Cambridge Antibody Technology. .
Businesses divested from the Company since merger are included up to the date of divestment. For example, data for Marlow Foods is included up to and including Q1 2003 and data for Durascan is included up to and including Q2 2004. The exceptions to this are Zeneca Agrochemicals, whose divestment was envisaged at the time of the merger, and also joint ventures.
After AstraZeneca was formed in April 1999, we introduced a new reporting system to monitor safety, health and environmental data. These data are received quarterly from all parts of AstraZeneca by the AstraZeneca SHE department. This includes AstraTech activities worldwide, and, as from Q1 2005, Aptium Oncology (US). Each facility is required to report performance against a set of criteria defined in a global reporting procedure. The data are evaluated and management reports are generated. Currently 158 submissions of data are received from 107 locations in 60 countries. We are currently working with MedImmune to effectively align our SHE programmes at a strategic level but at this time, MedImmune (including former CAT) performance is not included in this data
Regular review of the data is carried out to ensure accuracy and consistency. This has led to slight changes in the statistics produced for previous years. None of the changes is statistically significant. The statistics quoted in this report are generated from the revised data. The content of this page was externally assured by Bureau Veritas, February 2008
|